4,4-dimethyl-N-(2-methylbutan-2-yl)pentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4,4-dimethyl-N-(2-methylbutan-2-yl)pentanamide
• 化学式: C₁₂H₂₅NO
• 分子量: 199.33
• InChiKey: BGMZGSVIBKAXNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• CNP prodrugs with large carrier moieties
  申请人：ASCENDIS PHARMA GROWTH DISORDERS A/S

  公开号：US11154593B2

  公开（公告）日：2021-10-26

  The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.

  本发明涉及一种 CNP 原药或其药学上可接受的盐，包括 CNP 分子-D；和载体分子-Z，该载体分子-Z 通过分子-L2-与可逆原药连接分子-L1-共轭，该可逆原药连接分子-L1-与-D 共价可逆连接；其中-L2-是化学键或间隔物；而-Z 是分子量至少为 10 kDa 的聚合物。它还涉及包含 CNP 原药或其药学上可接受的盐的药物组合物、其作为药物的用途以及治疗方法。
• CNP PRODRUGS WITH LARGE CARRIER MOIETIES
  申请人：ASCENDIS PHARMA GROWTH DISORDERS A/S

  公开号：US20210177942A1

  公开（公告）日：2021-06-17

  The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L 2 - to a reversible prodrug linker moiety -L 1 -, which reversible prodrug linker moiety -L 1 - is covalently and reversibly conjugated to -D; wherein -L 2 - is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.